CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel-How Far Science Has Come.
In this phase I pharmacokinetic study of ABI-007, which was published in the May 1, 2002, issue of Clinical Cancer Research, Ibrahim and colleagues provided the framework needed for subsequent studies to confirm the benefits of ABI-007 over solvent-based formulations. Since the study's publication, experiments have highlighted the importance of drug-delivery systems, the immune system in cancer biology, and immunoregulatory properties of taxane compounds.
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sami I
SI
Bashour
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. nibrahim@mdanderson.org.
Nuhad K
NK
Ibrahim
D000068196:Albumin-Bound Paclitaxel / Q000494:pharmacology*; D000846:Anniversaries and Special Events; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D006801:Humans; D053758:Nanoparticles / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*
D000068196:Albumin-Bound Paclitaxel; D000970:Antineoplastic Agents